Neuropace Inc Stock Price, News & Analysis

NeuroPace, Inc. (Nasdaq: NPCE) reported preliminary unaudited revenue for Q4 and full-year 2021. Q4 revenue is expected at $11.0 million, a 2% increase year-over-year, with initial implant revenue at $8.5 million (10% growth). However, replacement implant revenue declined by 19% to $2.5 million. Full-year revenue is anticipated at $45.2 million, up 10% from 2020, driven by $33.7 million from initial implants (20% growth), but replacement implant revenue dropped 12% to $11.5 million. NeuroPace plans to present detailed financial results in March 2022.

NeuroPace, a medical device company focused on epilepsy treatment, announced its participation in the 40th Annual J.P. Morgan Healthcare Conference. CEO Mike Favet, CFO Rebecca Kuhn, and General Counsel Irina Ridley will present virtually on January 12, 2022, at 8:15 AM PT / 11:15 AM ET. A live webcast and subsequent archived recording will be available for 90 days on the company's website. NeuroPace's RNS System offers a unique, brain-responsive platform aimed at improving the lives of epilepsy patients by delivering real-time treatment.

NeuroPace, a medical device company focused on epilepsy treatment, reported Q3 2021 revenue of $10.3 million, a 19% decrease from last year. Initial implant revenue was $7.8 million, down 15%, influenced by COVID-19 disruptions. The company received IDE approval for a study on drug-resistant epilepsy and submitted a supplement for extending battery life claims of its RNS neurostimulator by two years. Operating expenses increased to $13.8 million, leading to a net loss of $8.1 million. Full-year guidance estimates total revenue between $44 million to $44.5 million.

NeuroPace has received FDA Investigational Device Exemption for its RNS® System to study treatment of drug-resistant idiopathic generalized epilepsy (IGE) in patients aged 12 and older. The NAUTILUS study will be the first in the U.S. to evaluate brain-responsive neuromodulation for IGE treatment, starting patient enrollment in 2022. The RNS System aims to improve life quality by monitoring and responding to patients' unique brain patterns. Previously, it received Breakthrough Device Designation from the FDA for this condition.

NeuroPace, Inc. (Nasdaq: NPCE) announced it will release its third-quarter 2021 financial results on November 10, 2021, after market close. Following the results, the company's management will host a conference call at 1:30 p.m. PT, available via dial-in or through a live webcast on their website. NeuroPace specializes in medical devices aimed at treating epilepsy, utilizing its innovative RNS System which provides personalized neuromodulation therapy to patients with drug-resistant seizures.

NeuroPace (Nasdaq: NPCE) announced on October 19, 2021, the appointment of Lisa Andrade to its Board of Directors, effective November 1, 2021. Andrade brings over 25 years of experience in the medtech sector and is currently the CEO of M33. She has held key positions at St. Jude Medical and possesses expertise in strategy, product development, and marketing. Additionally, Evan Norton is resigning from the board. Andrade expressed excitement about contributing to NeuroPace’s mission to transform epilepsy care with its RNS® System, approved for drug-resistant focal epilepsy.

MOUNTAIN VIEW, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) announced participation in three significant healthcare conferences. The schedule includes:

• Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 9:20 a.m. ET.
• Morgan Stanley Global Healthcare Conference on September 14, 2021, at 3:30 p.m. ET.
• Baird Global Healthcare Conference on September 15, 2021, at 2:35 p.m. ET.

Live audio will be available on the company’s website, with archives accessible for at least 90 days post-event.

NeuroPace, based in Mountain View, reported a 65% revenue increase to $12.6 million for Q2 2021. Initial implant revenues surged 100% to $9.2 million. The company received a $9.3 million grant from NIH's BRAIN Initiative to evaluate its RNS System for Lennox-Gastaut Syndrome. Despite increased revenues, operating expenses rose to $14 million, leading to a net loss of $8.5 million. NeuroPace forecasts a full-year revenue of approximately $47 million, a 14% growth year-over-year, but anticipates declining replacement implant revenues due to extended device battery life.

NeuroPace, Inc. (Nasdaq: NPCE) will report its financial results for Q2 2021 on August 12, 2021, after market close. A conference call with management will follow at 1:30 p.m. PT/4:30 p.m. ET, accessible by dialing (844) 955-2173 for domestic or (914) 987-7949 for international participants. NeuroPace specializes in innovative medical devices for epilepsy, with its RNS System being the only brain-responsive neuromodulation platform available, providing personalized treatment to patients with drug-resistant epilepsy.